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ABSTRACT 
For patients with chronic kidney disease (CKD) who develop kidney failure, renal replacement therapy 
(RRT) with kidney transplantation is the best treatment option. But if this is not possible due to lack of 
organs or medical factors, dialysis initiation with haemodialysis (HD) or peritoneal dialysis (PD) is 
required. Unplanned start (UPS) of dialysis using in-centre HD with central venous catheter (CVC) as 
default option is common and associates with increased mortality and lower chance of receiving PD.  
Educating and providing PD to UPS patients is possible and with clinical outcomes comparable to UPS 
with HD. As RRT patients have increased cardiovascular disease (CVD) related mortality - due to not 
only traditional risk factors but also non-traditional risk factors such as inflammation, oxidative stress, 
endothelial dysfunction and protein energy wasting – there is a need to identify biomarkers reflecting 
such risk factors.  
This thesis consists of three studies aimed to improve the knowledge about patient education in 
conjunction with dialysis initiation and in particular the effect of the unplanned education programme 
(UPS-EP) on clinical outcomes of UPS patients, and two studies of the predictive role of two putative 
clinically useful biomarkers (S100A12 and pentosidine) which are components of AGE-RAGE pathway.  
In Study I we evaluated the feasibility and impact of UPS-EP to allow modality choice in 270 patients. 
Patients completing UPS-EP were more likely to select PD as their preferred modality. Patient survival 
in patients choosing and/or receiving PD was similar to HD despite age and comorbidity disadvantages 
of the PD patients. 
In Study II, factors influencing three key steps in the UPS patient educational pathway: (1) referral to 
and receiving UPS-EP, (2) making decision on dialysis modality, (3) receiving preferred dialysis 
modality after decision making were analyzed. Older age reduced probability of receiving UPS-EP but 
not the chance of making modality decision. Cultural country factors had strong influence on probability 
of receiving education and making modality decision.  
In Study III we compared UPS patients commencing dialysis with PD catheter or CVC, described 
characteristics of patients switching modality, evaluated patient outcomes such as PD technique failure 
and investigated predictors of permanent vascular access formation and clinical outcomes of patients 
undergoing HD during follow up. Older patients and those with congestive heart failure had lower 
chances receive arteriovenous fistula (AVF). Patients with AVF had better 1-year survival than those 
remaining on CVC.  
In Study IV we investigated circulating S100A12 and soluble RAGE (sRAGE) in relation to peripheral 
or cerebrovascular disease (PCVD), inflammation, nutritional status, and mortality risk in PD patients. 
Plasma S100A12 and sRAGE were markedly elevated and sRAGE was inversely related to body mass 
indices while S100A12 associated with increased inflammation, PCVD, and mortality, suggesting that 
S100A12 may identify PD patients at high risk for vascular disease and increased mortality. 
In Study V we evaluated factors linked to increased plasma pentosidine and associations with mortality 
in patients with different stages and treatment of CKD. Plasma pentosidine was markedly elevated and 
associated with low GFR, oxidative stress and inflammation, and it predicted all-cause and CVD 
mortality. Despite exposure to glucose containing dialysis fluids in PD patients, their plasma pentosidine 
concentrations were not higher than in HD patients indicating that other factors than glucose exposure 
matters.  
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THESIS SUMMARY 
People who develop terminal kidney failure need to undergo renal replacement therapy (RRT). 
Kidney transplantation is recognised as the best treatment option but may not be possible due to 
lack of organs or because of advanced age and comorbidity and patients who cannot be 
transplanted need to choose between the two dialysis modalities, haemodialysis (HD) and 
peritoneal dialysis (PD). Despite advancements in dialysis technique and peri-dialysis care, still 
up to 50% of patients commence dialysis in an unplanned way which associates with poor 
clinical outcomes and lower chance to select home dialysis as the preferred dialysis modality 
which may lead to higher utilisation of healthcare resources. Regardless of dialysis modality, 
patients receiving RRT have high mortality with cardiovascular (CVD) disease as the major 
cause of death, which cannot be solely explained by traditional risk factors. As non-traditional 
risk factors typical for the state of uraemia such as inflammation, oxidative stress, endothelial 
dysfunction and protein energy wasting also play a pivotal role, there is a need to identify 
biomarkers that reflect such risk factors in this particular patient population. The current thesis 
consists of five studies that aimed to contribute to the current knowledge about patient education 
in conjunction with dialysis initiation and the predictive role of putative clinically useful 
biomarkers.  
In studies 1-3 we evaluated how patients starting unplanned dialysis can be supported to make 
an informed choice between starting on HD and PD, and found that it is feasible to provide a 
structured educational programme to the majority of unplanned start patients allowing many of 
them to make a decision about their preferred dialysis treatment option. However, not all patients 
receive their preferred modality which may be related to country specific settings or logistic 
challenges and other factors that require further investigation. These studies show that it is 
worthwhile to educate patients who commence unplanned dialysis and that this may favour 
selection of PD as initial dialysis modality which may have medical and cost benefits.  
In studies 4 and 5 we evaluated biomarkers S100A12 and pentosidine as predictors of patient 
outcomes and showed that elevated plasma concentrations of S100A12 and pentosidine are 
associated with increased all-cause mortality and for pentosidine also with increased CVD-
mortality. These biomarkers may add value to the prognostic information or as putative targets 
for interventions aiming at improving patient clinical outcomes.  

1 
1. INTRODUCTION 
1.1 CHRONIC KIDNEY DISEASE 
Chronic kidney disease (CKD) is emerging as an important public health problem and a global 
concern for healthcare systems. The prevalence of CKD has reached epidemic proportions with 
10%–12% of the population and 50% of elderly showing signs of kidney dysfunction, a 
condition associated with high morbidity and mortality (1). According to Kidney Disease 
Improving Global Outcomes (KDIGO) guidelines, CKD is defined as abnormalities of kidney 
structure or function, present for more than 3 months, with implications for health (2) and can 
be divided into five stages assessed by glomerular filtration rate (GFR). CKD is usually 
characterized by a progressive course of worsening renal function eventually leading to the last 
stage, CKD 5, also called end-stage renal disease (ESRD), when GFR falls below 15 ml/min 
per 1.73 m2 and the patient may require renal replacement therapy (RRT) to survive. Several 
RRT modalities are available for the treatment of ESRD; most patients will be treated using 
renal transplantation or dialysis while some patients may be managed conservatively (3). 
1.2 RENAL REPLACEMENT THERAPY 
Although successful kidney transplantation is by far the best treatment option in regards to 
survival, health-related quality of life (HRQOL) and costs saving, the lack of available donor 
organs, increasing patient age, burden of comorbid conditions and patient choice precludes 
transplantation in many ESRD patients. As a result chronic dialysis, either with peritoneal 
dialysis (PD) which utilizes the peritoneal membrane as a dialysis filter, or with haemodialysis 
(HD) entailing extracorporeal cleansing of blood, is very often the only available option for 
ESRD patients. 
1.3 CLINICAL OUTCOMES OF PATIENTS ON PERITONEAL DIALYSIS AND 
HAEMODIALYSIS 
Peritoneal dialysis (PD) and haemodialysis (HD) are complementary therapies sustaining 
survival in patients with ESRD. Clinical outcomes associated with both modalities should be 
considered during the dialysis decision-making process, since a difference in survival would 
influence the use of the two modalities. The difference in mortality seen in observational studies 
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with PD compared to HD has been widely debated for many years. An initial survival advantage 
of PD therapy was observed in Danish patients within the first 2 years of dialysis (4). 
NECOSAD (Netherlands Cooperative Study on The Adequacy of Dialysis) showed that the 
relative survival benefit of PD compared with HD among participants decreased over time (5). 
This finding was supported by another study from The Netherlands (6) showing that the relative 
mortality risk of PD patients compared with HD patients increased over time (survival benefit 
of PD diminished). Data from the Australian and New Zealand registry also showed lower 
mortality risk among patients who were treated with PD during the first 12 months (7). In the 
US, the survival difference between PD and HD was consistent with the data from Australia (8). 
More recent data from the US showed no significant difference in the risk of death for HD and 
PD patients during 5-year follow-up, and that the survival for PD patients is improving (9). Data 
from Canada also show similar outcomes with the two techniques (10).  
Although the findings have not always been entirely consistent (11) most data show survival 
advantage of PD treatment during the first year(s) of therapy. Therefore, “integrative care” 
approaches; in which patients commence dialysis with PD and then are transferred to HD - when 
mortality risk increases - seem to be beneficial from the perspectives of both the patient and the 
healthcare providers.  
1.4 DIALYSIS INITIATION 
The optimal time of dialysis initiation has been disputed since 1980s‘when Bonomini 
et al (12) from Bologna, Italy, reported that earlier initiation of dialysis could convey increased 
patient survival. In CKD patients the risk of all-cause and cardiovascular mortality increases 
with decline in renal function, especially when the glomerular filtration rate (GFR) decreases 
below 60 mL/minute (13). As patients with CKD are more likely to die than progress to renal 
replacement therapy, (14) it is natural to ask whether the high mortality risk in patients with 
CKD stages 4 to 5 can be reduced by earlier dialysis initiation. On the other hand, if the dialysis 
procedure is associated with factors leading to increased risk of morbidity and mortality (15) 
what is the added risk by starting dialysis earlier rather than later: would in fact earlier dialysis 
initiation instead increase the mortality risk?  
Several observational studies had been performed to investigate the clinical outcomes of patients 
starting dialysis at various levels of estimated GFR (eGFR) showing that early start of dialysis 
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especially when using in centre-haemodialysis (HD) as initial therapy potentially could be 
harmful and also questioned the trend to early dialysis initiation based solely on eGFR; the 
clinical status of the patients, besides eGFR levels, should also be taken into account in the 
decision making process. These studies showed that the outcome after dialysis initiation was 
not only affected by GFR and patient characteristics but also appeared to associate with the type 
of dialysis (16-22). 
There are many reasons why PD could be advantageous as initial dialysis therapy: better initial 
patient survival, preservation of vascular access sites, and higher haemoglobin and less EPO 
use, and better preservation of residual renal function compared to in-centre HD (23).  
There is a continuously increasing interest in using PD also for patients commencing dialysis in 
unplanned, acute settings. The “PD First Strategy” is considered a suitable option for those 
patients as clinical outcomes of urgent PD are comparable with urgent HD start (24). 
1.4.1 Factors influencing dialysis modality choice 
Dialysis modality selection and distribution is of fundamental importance for patients and 
healthcare providers. The decision about modality selection must be influenced by a wide range 
of factors not related to the clinical evidence since the utilization of home therapy varies widely 
worldwide. According to the United States Renal Data System (USRDS), the rate of PD varies 
from 1.7% in Bangladesh to 74.1% in Hong Kong (25). This large difference cannot be 
motivated by any of the published global clinical evidence (4-10). Furthermore, registry data 
(25) show similarities in the incident dialysis population between comparable countries with no 
clear evidence that there are major age or comorbidity differences at dialysis start capable of 
explaining the differential use of the two modalities. In a review of secondary data from 
European Observatory and also data on population and demographics published by Eurostat and 
the World Health Organization (WHO) (26), we described several factors as main driving forces 
towards PD utilization disparities by affecting patient-doctor interaction and therefore decision 
process, such as healthcare system organization, socioeconomic factors and personal 
preferences of patients and health care professionals. These influential factors are presented as 
a theoretical construct in Figure 1. Considering all the factors, it was proposed that centre-
specific differences within a country involving individual nephrologists’ attitudes, beliefs, PD 
knowledge and practice organization and/or infrastructure, had a strong influence on PD use.  
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Careful clinical management is crucial and several factors such as early referral to nephrologist, 
better coordination of medical care, management of CKD complications, and education around 
dialysis options that is based on informed consent may contribute not only to better clinical 
outcomes of RRT and but also decrease the probability of unplanned start (UPS) dialysis and 
increase the number of patients choosing home dialysis therapy. 
 
Figure 1. Factors that may influence PD use in Europe. All factors are changing over time and 
need to be considered by all stakeholders in considering current and future service provision 
(26). 
 
1.4.2 Unplanned dialysis start 
Unplanned start (UPS) of dialysis remains a worldwide concern and it is estimated that 24-49% 
of patients commence dialysis in such a way (27). UPS patients have more clinical problems 
such as increased morbidity and mortality (28), require increased use of healthcare resources 
(e.g. hospital days) (29), are less likely to receive a choice of dialysis modality and choose a 
home dialysis therapy, and typically start more often on in-centre HD compared with patients 
starting planned dialysis (30). Much of the problems related to UPS is access driven; patients 
starting with a central venous catheter (CVC) have much higher mortality risk as compared with 
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those using PD or start HD with arteriovenous fistula (AVF) or arteriovenous grafts (AVG) (31) 
and have increased risk of septicaemia (32). 
The definition of unplanned start (UPS) of dialysis varies which can make comparisons difficult 
but in most studies UPS is defined, at least in part, when first dialysis has to take place despite 
lack of functional AV fistula or permanent PD catheter. Recently the term “suboptimal” dialysis 
was proposed to define dialysis commenced as a hospital in-patient, and/or with CVC (without 
permanent access) (33). Other criteria for defining UPS have also been proposed: 
(1) Time between referral to the nephrology unit and first dialysis with a range, defined for 
late referral, between 1-6 months. Late referral is not entirely synonymous with UPS; 
however, early referral tends to be a predictor of better coordination of medical care in 
pre-dialysis stage, management of CKD complications, and education around dialysis 
option that is based on informed consent, and may therefore decrease probability of UPS. 
A recent meta-analysis shows that early referral is associated with reduced mortality and 
hospitalization, greater uptake of PD and timely placement of permanent dialysis access 
(34). This is clinically important as patients who start dialysis with CVCs have increased 
chances of prolonged CVC use and associated complications (35). 
(2)  Biochemical parameters e.g. estimated glomerular filtration rate (eGFR) - defined as 
early (above a certain level of eGFR) or late (below that level of eGFR) start which can 
be misleading as it does not reflect a clinical pathway. The randomized, multicentre, 
controlled IDEAL study aimed to evaluate the optimal dialysis start based on eGFR (17) 
of early vs late initiation. There was no difference in terms of survival between these 
eGFR defined groups but more patients in the “late” start category had UPS with 
temporary access.  
(3) Speed of the need for dialysis - emergent dialysis, urgent dialysis and non-urgent dialysis 
as defined by Ghaffari (36): Emergent start < 48 hours, urgent start > 48 hours and up to 
2 weeks, whilst non-urgent start were those that were able to plan and start with their 
modality of choice (36).  
(4) Being known or “unknown” to nephrology care. There are “known” patients that despite 
nephrology follow up, have UPS due to unpredictable GFR decline or care pathway 
failures. In addition, there is a cohort of truly “unknown” patients that present with 
undiagnosed CKD stage 5. 
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1.4.3 Educational aspects of unplanned start 
The choice of initial dialysis modality should ideally be made primarily by well-informed 
patients. In planned start patients, education programs significantly affect the distribution of 
dialysis modalities, increasing the proportion of patients on PD and optimizing the pre-dialysis 
management process (37). European guidelines (38) state that all RRT centres should provide 
patients and their families with well-balanced information about the different RRT modalities 
by means of a structured education program and this applies also to late referred and UPS 
patients. 
The clinical concerns remain over whether it is feasible to educate UPS patients about different 
modalities and whether the system of care in dialysis units can be organized to educate and 
deliver choice of dialysis modality. Undoubtedly, the education about dialysis options of UPS 
patients is a challenge for every dialysis unit and it can be perceived that such patients with 
intense and urgent medical needs cannot be educated or make a choice. However, the results of 
single centre studies show that it is possible to educate UPS patients (39) and that UPS patients 
can commence PD (36, 40, 41), and that unplanned PD can give similar outcomes compared to 
unplanned HD (24, 42).  
1.5 BIOMARKERS 
According to the definition proposed by National Institute of Health (NIH) a biomarker is “a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
process, pathogenic processes, or pharmacologic response to a therapeutic intervention”.  
An ideal biomarker with clinical relevance should be accurate, reproducible, and measurable at 
a reasonable cost. In addition, it should have strong and consistent association with outcome in 
different cohorts. Finally, it should be practically informative enough to guide the clinician to 
make clinical decisions. It should be emphasized that useful clinical biomarkers may not 
necessarily be risk factors per se, although they reflect the pathogenic process (43).  
The usefulness of the biomarker can be estimated by its: (1) prognostic value as a clinical or 
biological characteristics that is objectively measurable and that provides the information on the 
likely outcome of the disease or (2) predictive value as a clinical or biological characteristics 
that provides information on the likely benefit from treatment or (3) mechanistic value in that it 
enhances our understanding of the cause-and-effect pathway. 
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1.5.1 Novel biomarkers for cardiovascular disease (CVD) 
Cardiovascular disease is a significant cause of morbidity and mortality in patients with ESRD. 
Identifying and intervening against common risk factors is a priority, but traditional 
Framingham risk factors are poor predictors in late stage chronic kidney disease (CKD) patients 
(1, 43-46), suggesting that the pathophysiological mechanisms may differ compared to the 
general population. Therefore non-traditional risk factors such as advanced glycated end 
products (AGEs) which play role as significant risk factors for CVD and contribute to other long 
term complications are of potential great interest in CKD. 
1.6 ADVANCED GLYCATED END PRODUCTS (AGEs) 
AGEs are formed in the body as a result of non-enzymatic processes of covalent bonding of 
molecules in proteins, lipids and nucleic acids with glucose or other saccharide derivatives. The 
process of formation of AGEs, known as Maillard reaction, starts with the formation of early 
glycation products called Shiff bases and Amadori products (47) that are formed in proportion 
to glucose concentration (48). The early glycation products are still in equilibrium with plasma 
glucose, and when glucose levels fall, the early glycation products can dissociate to the native 
proteins. Alternatively, if glycation continues, molecular rearrangement occurs, resulting in 
formation of the AGEs (49). The formation of AGEs is enhanced under specific conditions such 
as hyperglycaemia, oxidative stress and inflammation (50). Chronic uremia is a state of 
increased oxidative stress, and redox imbalance accelerates the accumulation of AGEs (51). In 
the presence of these conditions intra- and extracellular proteins can be glycated and oxidized 
resulting in accumulation of AGEs in essentially all tissues and body fluids. The impairment of 
renal function leads to reduced disposal and increased accumulation of AGEs (52) which are 
also naturally formed during aging processes and in specific pathological circumstances such as 
diabetes (53).  
AGEs formation causes pathological changes via three general mechanisms including: 
modification of extracellular matrix (ECM), alteration of the action of cytokines, hormones, and 
free radicals - through interactions with AGE-specific cell surface receptors (3) - impact on the 
function of intracellular proteins (50).  
In the ECM, glycoxidation alters the internal structure of the proteins by cross-linking with 
different molecules such as lipids, collagen, laminin, elastin and vitronectin that leads to 
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permanent changes in matrix constitution and increases the stiffness of the vasculature. Also, 
the activation of the transforming growth factor (TGF)-ȕ receptor stimulates cell growth leading 
to increased ECM production (54-56). The mechanisms of interactions between AGEs and 
receptor for AGEs (RAGE) on the endothelial cell surface that triggers intracellular signalling 
cascade is described below. 
1.6.1 Receptor for AGEs 
Monocytes and macrophages were the first cells on which a high-affinity receptor for AGE 
(RAGE) was identified. In these studies, the interaction of AGE-protein with mouse peritoneal 
macrophages, using AGE-modified bovine serum albumin was characterised (48). The RAGE 
was cloned and expressed for the first time by Neeper et al. (57) who indicated this receptor as 
a new member of the immunoglobulin superfamily (49). AGEs interact with RAGE on the 
endothelial cell surface, and this triggers intracellular signalling cascades resulting in 
stimulation of NAD(P)H oxidase, increased level of reactive oxygen species (ROS) but also in 
upregulation of a key target: transcription factor NF-ț%. In the next step NF-ț%is translocated 
to the nucleus where it transcribe its target genes such as endothelin-1, intracellular adhesion 
molecule-1 (ICAM-1), E-selectin and also pro-inflammatory cytokines like interleukin-Į,/-
Į interleukin-6 (IL-6), tumour necrosis factor-ĮTNF-Į and RAGE itself (47). RAGE is a 
multi-ligand receptor which can bind not only AGEs, but also to diverse group of ligands such 
as S100/calgranulins, amphoterin and high-mobility group box 1 (HMGB-1) (58). Soluble 
RAGE (sRAGE) is shed from cellular membranes into circulation where it plays role as a decoy 
receptor that competitively binds circulating ligands including AGEs, thereby antagonizing 
intracellular RAGE signalling and alleviating pro-inflammatory effects of these ligands (59). In 
chronic inflammatory conditions such as CVD, sRAGE levels are low, while high levels of 
endogenous secretory RAGE are thought to be anti-inflammatory and protective against 
atherosclerotic CVD (60). 
1.6.2 EN-RAGE (extracellular newly identified RAGE-binding protein), also known as 
S100A12 
This calcium-binding protein EN-RAGE, also known as S100A12 is expressed on the surface 
of macrophages, lymphocytes and endothelium at sites of local inflammation where it 
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participates in AGE-RAGE inflammatory response (61). S100A12-RAGE interaction drives  
pro-inflammatory gene transcription through NF-ț%DFWLYDWLRQ and upregulation of adhesion 
molecules ICAM-1 and VCAM-1 in vascular endothelial cells and (62). It also enhances 
migration and activation of monocytes and increase pro-inflammatory cytokine production in 
macrophages (63). These mechanisms suggest the potential contribution of S100A12 to the 
development of atherosclerosis. In PD, the heat sterilization process of glucose-based PD fluids 
could lead to glucose degradation products, contributing to accelerated AGE formation and 
therefore over-expression of RAGE. In PD patients the plasma concentration of S100A12 is 2 
to 3-fold higher compared to healthy subjects and associates with carotid atherosclerosis (64). 
The association between high level of S100A12 and mortality was described in CKD stage 5 
patients starting on dialysis (65), prevalent HD patients (66) and also in prevalent PD patients 
(67).  
1.6.3 Pentosidine 
Pentosidine is a well-characterized, fluorescent AGE structure, described for the first time by 
Sell and Monnier in 1989 (68). Pentosidine formation is caused by the highly reactive carbonyl 
compound 3-deoxyglucosone that links with the amino groups of proteins. In the circulation of 
uremic patients, pentosidine accumulates as both free and albumin-linked form (69). Kidneys 
play a key role in excretion of AGEs. The results of a study in a rat model suggest that free 
pentosidine (and possibly other AGEs) is filtered through renal glomeruli, reabsorbed in the 
proximal tubule where it is degraded or modified, and eventually excreted in the urine (70). 
Therefore, it is expected that the level of AGEs increases with the decline of renal function. 
Studies in PD patients showed that loss of residual renal function (RRF) is associated with 
increased plasma pentosidine and advanced oxidized protein products (AOPP), showing the 
beneficial role of RRF in reducing oxidative and carbonyl stress (71). Associations between 
pentosidine levels, biomarkers related to inflammation, malnutrition, CVD and clinical 
outcomes have been investigated in multiple studies. In CKD stage 5 patients investigated 
before starting dialysis, plasma pentosidine associates with inflammation and malnutrition (72). 
Circulating pentosidine associates with progression of atherosclerosis indicated by changes in 
carotid intima-media thickness during the first year of PD and HD therapy (73). HD patients 
with higher plasma pentosidine had increased risk for cardiovascular events (74), accelerated 
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rate of progression of aortic stiffness (75) and exhibited negative association with carotid 
dispensability suggesting its role in the development of arterial stiffness (76). However, other 
studies showed no relationship between plasma pentosidine, intima media thickness and the 
number of atherosclerotic plaques (77). The contribution of pentosidine to the development of 
cardiovascular events and mortality in CKD patients is still disputed (78) and traditional risk 
factors in ESRD patients have been reported to be more important for cardiovascular outcomes 
than elevated levels of AGEs (79).  
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2. AIMS 
 
Overall aim 
The overall aim of the investigations summarized in this thesis is to present the role and impact 
of unplanned start education programme on the clinical outcome of patients commencing 
dialysis in unplanned manner and also to evaluate the prognostic role of biomarkers related to 
AGE-RAGE pathway and its association with cardiovascular disease and mortality.  
 
Specific aims 
Paper I. To investigate the feasibility and impact of the unplanned start education programme 
(UPS-EP) on the dialysis modality choice in patients commencing dialysis in unplanned manner. 
Paper II. To investigate the factors that may influence receiving education, decision making 
process and enacting on the dialysis modality decision made by unplanned start patients. 
Paper III. To evaluate the impact of the initial dialysis access on patient clinical outcomes and 
its relation with hospitalization, dialysis related procedures and infections. 
Paper IV. To study the association between circulating S100A12 (EN-RAGE, extracellular 
newly identified receptor for advanced glycated end products binding protein) and presence of 
cardiovascular disease (CVD) and mortality in PD patients. 
Paper V. To compare the level of pentosidine in CKD patients with different stages of CKD and 
to investigate the prognostic role of pentosidine in CVD and all-cause mortality.  
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3. PATIENTS AND METHODS 
The work presented in this thesis is based on five observational cohorts. In study I, II and III 
we used the data from Offering Patient Therapy Options in Unplanned Start (OPTiONS) study. 
In study IV we used material from Mapping of Inflammation Markers in Chronic Kidney 
Disease 1 (MIMICK-1; prevalent HD patients) and Mapping of Inflammation Markers in 
Chronic Kidney Disease 2 (MIMICK-2; prevalent PD patients) cohorts. In study V we used 
material from MIMICK-1 and MIMICK-2 cohorts, and from cohorts of patients with CKD stage 
5 initiating dialysis (Malnutrition, Inflammation and Atherosclerosis, MIA) and patients with 
CKD stage 3-4 (PRIMA) respectively as well as community-dwelling control subjects.  
3.1. PATIENTS AND METHODS IN STUDY I, II AND STUDY III 
3.1.1 Offering Patients Therapy Option in Unplanned start (OPTiONS) 
This was a non-interventional, multi-centre, observational study of 270 unplanned start (UPS) 
patients, who were followed up for 12 months. Twenty-six centres in six European countries 
(Austria, Denmark, Germany, France, Sweden and United Kingdom) agreed to recruit all UPS 
patients presenting in their units. In these centres, all UPS patients were identified on clinical 
presentation and considered actively for education within the structured unplanned start 
education programme (UPS-EP) with the use of decision support tools. UPS patients who were 
judged clinically to not be suitable for this educational approach or who would not be able to 
make a modality choice for medical reasons were still identified and included in the overall UPS 
cohort. Patients could receive the UPS-EP at the time of presentation or following dialysis start. 
The study inclusion criteria were CKD stage-5, age between 18 and 90 years at the time when 
informed consent was signed, and dialysis commenced in an unplanned way on the basis of 
clinical criteria of presentation to the nephrologist within one month of needing dialysis (as 
‘unknown” patient) AND/OR being followed by nephrologist but requiring urgent dialysis 
commencement by central venous catheter (CVC) or an acutely placed PD catheter. The 
exclusion criteria included: diagnosis of acute kidney injury (AKI) rather than CKD stage 5 as 
defined by NICE Guideline (80); clinical decision to actively follow a conservative clinical 
management plan (chronic dialysis not planned); and, other serious or acute conditions that, in 
the investigator’s opinion, would preclude participation in the study or where life expectancy 
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was estimated at 6 months or less. Patients gave informed consent for inclusion and data 
collection at the time of UPS presentation or in the recovery phase around the time of hospital 
discharge. The ethics approval were granted by all appropriate ethics committees: Regionala 
etikprövningsnämnden i Stockholm (EPN), 2012/2:2; West Midlands MREC, UK 11/WM0160; 
Ethikkomission der Atrzekammer Nordrhein, 2011222; Ethikkomission der Atrzekammer 
Saarlandes, 127/11; Ethikkomission Tubingen, 376/2011B02; Ethikkomission der 
Atrzekammer, Stuttgart 1816/BX; Ethikkomission der Bayerischen, Munich 11068; 
Ethikkomission der Medizinischen Universitat Wien, Vienna 605/2011; CNIL, Paris 
EGY/ABE/AR122444; CNOM, Paris FR/IH/SRMI/CN-11-349-117; CCTIRS, Paris 11.688.  
3.1.2 Unplanned start education programme (UPS-EP) 
The UPS-EP was developed in an attempt to modulate the UPS patients’ pathway and allow 
dialysis modality education and modality decision making by UPS patients. The program is 
composed of an education program, together with an examination and optimization of the flow 
of UPS patients in renal care units. The program was developed in collaboration with five 
European dialysis units linked to academic institutions specialized in patient education. The 
program is focused on facilitating the decision making process for patients choosing chronic 
RRT. Thus, the UPS-EP material included information on HD, PD, home HD and conservative 
care as well as transplantation. The UPS-EP was delivered to the patients during at least three 
individual sessions by nurses using motivational interviewing methodology, at a pace 
determined by the educational nurse with assessment of the clinical condition.  Supporting 
materials included a dialysis options booklet matching the educational material delivered by the 
nurse, a photograph based book showing PD, HD and home HD, and a unit-specific video of 
the techniques alongside visits to the HD unit and demonstration of PD. In addition, decision 
support tools were used as key elements of UPS-EP whereas their use in CKD education at the 
time of commencement of OPTiONS was minimal. Decision aids (decision support tools) 
present a detailed, specific and personalized picture of options and outcomes to prepare people 
for decision making. They differ from health education materials, which tend to be broader in 
perspective (helping people to understand diagnosis, treatment, and management but not 
assisting with a specific personal choice between options). Three aids were available to centres 
with the educators choosing for the individual patient from the Ottawa online decision aid, a 
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self-completion balance scale and a set of decision cards which allowed the patient to prioritize 
the value to them of specific issues and factors related to dialysis modalities.  
The UPS-EP also consists of analysis of UPS patient flow in a dialysis unit with process 
improvement approach to understand and resolve issues - the units mapped out their unplanned 
start pathway to understand and improve specific bottlenecks and constraints. The aim was to 
improve the pathway to patient education, decision making and formation of permanent access 
(AV fistula or peritoneal catheter). 
3.1.3 Data collection 
Demographic or clinical data were collected either from the patients’ healthcare records or from 
routine patient-health care professional interactions at baseline, 6 months and 12 months. This 
included patient demographics, medical history including comorbidities assessed by Charlson 
comorbidity index (CCI), dialysis access procedures, details of the presentation with end-stage 
renal failure requiring UPS and details of starting modality, access interventions and the number 
and length of hospitalization linked to UPS. Data collection at 6 months (defined as 6 months 
following first HD session or first PD day at home if PD from the start of dialysis) and 12 months 
(defined as 12 months following first HD session or first PD day at home if PD from the start 
of dialysis) recorded patient status, dialysis modality, and if, when changed, details of dialysis 
access procedures, brief details of dialysis related infectious events and number and length of 
any hospitalizations. The patients flow throughout the study is presented in Figure 3.1. 
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Figure 3.1 The flow of UPS patients during the study follow up time. 
 
3.1.4 Peritonitis and bacteraemia rate  
In studies I and III peritonitis rate was calculated according to ISPD guidelines (81) and 
expressed as months of PD at risk, divided by number of episodes, and expressed as interval in 
months between episodes and also as number of infections for a time period, divided by dialysis-
years’ time at risk, and expressed as episodes per year. 
In order to compare the severity of the infection events we applied the same calculation scheme 
to show the bacteraemia rate among HD patients calculated based on the number of 
haemodialysis bloodstream infection. In our study, the definitions are classified according to the 
KDIGO Vascular Access guidelines (82). Bloodstream infection was defined as blood culture 
results positive for the presence of bacteria with or without the accompanying symptom or fever. 
3.1.5 Hospitalization, procedures and infections 
In study III we calculated the cumulative incidence of dialysis access related procedures and 
hospitalization (admissions and length of time), the number of dialysis access related infections 
such as PD tunnel infection, PD exit site infection, peritonitis, HD tunnel infection, HD exit site 
infection, HD bloodstream events during the study period. The access related procedures were 
also categorized 4 groups according to the number of procedures: 0, 1-2, 3-RUSURFHGXUHV. 
3.1.6 Statistical analysis 
In studies I, II and III data are expressed as median (10th to 90th percentile), percentage, odds 
or hazard ratio (95% CI, confidence intervals), as appropriate. Statistical significance was set at 
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the level of p<0.05. For comparison between two groups non –parametric Wilcoxon test was 
used - and for three or more groups - non-parametric Kruskal-Wallis ANOVA test was used. 
Chi-square test was used for nominal variables. Kaplan Meier technique was used to calculate 
crude one-year patient and techniques survival. Statistical analyses were performed using 
statistical software SAS version 9.4 (SAS Campus Drive, Cary, NC, USA). 
In study I multivariate logistic regression was performed to determine factors predicting if 
patients would be receiving PD vs HD dialysis therapy during the study, including initial dialysis 
modality. Explanatory variables in the model include age, gender, eGFR, presence of diabetes, 
hospitalization for unplanned start, time between first referral to nephrologists and first dialysis 
session and received education.  
In study II multivariate logistic regression was performed to investigate the factors that may 
influence the key 3 steps in the education pathway: (1) receiving education, (2) making dialysis 
modality choice, and (3) receiving modality according to patient preferences. Depending on the 
model the following explanatory variables were included: age, gender, presence of diabetes, 
congestive heart failure (CHF), time between first referral to nephrologists and first dialysis 
session (categorized as needing dialysis at the referral day, or later), initial dialysis modality 
(modality to which patient was assigned by the physician), and center (countries were divided 
to two groups based on historical home dialysis use: France (FR), Germany (DE), and Austria 
(AU), and United Kingdom (UK), Sweden (SE), and Denmark (DK) respectively), and patient 
source (in-patient/out-patient admission as a proxy for timing of the education). 
In study III multivariate logistic regression was performed to investigate the factors that may 
predict presence of fistula. Explanatory variables included were: age, gender, received UPS-EP, 
presence of diabetes (DM) and presence of congestive heart failure (CHF). Multivariate Cox 
regression analysis adjusted for type of vascular access, age, sex, country and presence of CHF 
was performed to investigate one-year, all-cause mortality in patients who remained on 
haemodialysis therapy during whole period of the study (n=158). We estimated the crude one-
year technique failure in PD patients (n=72) using Kaplan-Meier technique, defining transfer to 
HD therapy as technique failure. 
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3.2 PATIENTS INCLUDED IN STUDY IV 
3.2.1 Mapping of Inflammation Markers in Chronic Kidney Disease 1 (MIMICK-1) 
The MIMICK-1 cohort comprises prevalent HD patients from six HD units in the Stockholm-
Uppsala region as described previously (83). This study originally aimed at monitoring 
inflammatory markers in prevalent HD patients. The recruitment of patients took place from 
October 2003 until March 2004. The inclusion criteria were more than three months on dialysis, 
and age >18 years. Exclusion criteria covered unwillingness to participate or infections such as 
human immunodeficiency virus (HIV) or methicillin-resistant Staphylococcus aureus (MRSA). 
In study IV we included 190 patients (106 men, median age of 67 years) from the MIMICK-1 
cohort with available measurements of S100A12 and sRAGE. The Ethics Committee of the 
Karolinska Institutet, Sweden, approved the study (Dnr.03/415). 
3.2.2 Mapping of Inflammation Markers in Chronic Kidney Disease 2 (MIMICK-2)  
This cohort comprises prevalent PD patients. The study primarily aimed to monitor 
inflammatory markers in all prevalent PD patients who were controlled at the Karolinska 
University Hospital at Huddinge and at Danderyd´s hospital in Stockholm who had been treated 
for at least three months on continuous ambulatory peritoneal dialysis (CAPD) or automated 
peritoneal dialysis (APD). The description of the study was presented previously (84). Among 
97 patients eligible for the study, 13 patients did not start the study due to transfer to HD, 
transplantation or death, and among 2 patients S100A12 and sRAGE could not be measured due 
to lack of serum sample. The study IV comprises 82 patients (70% of men, median age of 65 
years). Peritoneal dialysis was provided as CAPD to 77 % of the patients and APD to 23 % of 
patients. The patients were recruited from March 2008 to April 2011. The Ethics Committee of 
the Karolinska Institute at the Karolinska University Hospital Huddinge, (EPN) Stockholm, 
Sweden, approved the study protocol and informed consent was obtained from each patient. 
(Dnr 03/415, Dnr 2007/166331/4). 
3.2.3 Control subjects 
For comparative reasons, 50 community-dwelling and thus in most cases healthy subjects (31 
men, with median age of 63 years), randomly selected by Statistics Sweden (SCB, a government 
agency) from the region and who accepted to participate as volunteers, were included in the 
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analysis. In study IV the prevalent HD patients and control subjects underwent similar 
measurements as those of the prevalent PD patients. These individuals were recruited from 
February 2003 until April 2004. The Ethics Committee of the Karolinska Institute at the 
Karolinska University Hospital Huddinge, (EPN) Stockholm, Sweden, approved the study 
protocol and informed consent was obtained from each individual (Dnr 40/02). 
3.3 PATIENTS INCLUDED IN STUDY V 
3.3.1 Mapping of Inflammation Markers in Chronic Kidney Disease 2 (MIMICK-2) 
The description of the study was presented previously (84) and also above. In total, 74 prevalent 
PD patients (median age 61 years; 64% males) were included in study V. The Ethics Committee 
of the Karolinska Institute at the Karolinska University Hospital Huddinge, (EPN) Stockholm, 
Sweden, approved the study protocol and informed consent was obtained from each patient (Dnr 
03/415, Dnr 2007/166331/4). 
3.3.2 Mapping of Inflammation Markers in Chronic Kidney Disease 1 (MIMICK-1) 
The study was described previously (83) and also above. In total 195 prevalent HD patients 
(median age 64 years; 57% males) were included in study V. The Ethics Committee of the 
Karolinska Institute at the Karolinska University Hospital Huddinge, (EPN) Stockholm, 
Sweden, approved the study protocol and informed consent was obtained from each patient 
(Dnr.03/415)  
3.3.3 MIA cohort 
MIA cohort is an ongoing, prospective cohort study started in 1994 and described in more detail 
elsewhere (85, 86). Incident CKD stage 5 patients (GFR<15 mL/min) were evaluated close to 
start of dialysis (either HD or PD) at the Karolinska University Hospital at Huddinge, Sweden. 
Patients were followed up until death or transplantation. Patients were invited to attend an 
additional examination after approximately one and two years of dialysis therapy. In study V 
we included in total 386 patients, who were recruited from June 1994 until October 2012. The 
median age of patients was 55 years and 60% were males. The Ethics Committee of the 
Karolinska Institute at the Karolinska University Hospital Huddinge, (EPN) Stockholm, 
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Sweden, approved the study protocol and informed consent was obtained from each patient  
(Dnr. 273/94)  
3.3.4 CKD stage 3-4 
This cohort consists of 54 patients with CKD stage 3-4 recruited from the renal outpatient clinic 
of Karolinska University Hospital from December 2001 until March 2004. The description of 
the study was presented previously elsewhere (87). The median age of patients included in study 
V was 60 years, and 74% were males The Ethics Committee of the Karolinska Institute at the 
Karolinska University Hospital Huddinge, (EPN) Stockholm, Sweden, approved the study 
protocol and informed consent was obtained from each patient (Dnr 244/01) 
3.3.5 CKD stage 1-2 
In study V, 37 individuals with CKD stage 1-2 from a population based sample randomly 
selected by Statistics Sweden (a government agency) from the Stockholm region and who 
accepted to participate as volunteers were found to have signs of mild CKD (macro- or 
microalbuminuria or reduced GFR). These individuals were serving as controls and were 
included in the studies for comparative reasons for the CKD stage 3–4 patients and thus they 
have similar age and gender distribution as the CKD stage 3–4 patients. The median age was 68 
years and 70% were males. The individuals were recruited from February 2003 until April 2004. 
The Ethics Committee of the Karolinska Institute at the Karolinska University Hospital 
Huddinge, (EPN) Stockholm, Sweden, approved the study protocol and informed consent was 
obtained from each individual (Dnr 40/02). 
In addition, study V included 59 CKD patients from an ongoing study (Kärl-Tx) of vascular 
changes in patients undergoing living donor kidney transplant, LD-Rtx cohort. The patients in 
LD-Rtx cohort were allocated to the various groups in study V depending on their stage of CKD 
or dialysis treatment: One patient was allocated to CKD stage 3-4, 24 patients to CKD stage 5, 
17 patients to HD and 18 patients to PD. The Ethics Committee of the Karolinska Institute at 
the Karolinska University Hospital Huddinge, (EPN) Stockholm, Sweden, approved the study 
protocol and informed consent was obtained from each individual (Dnr 2008/1748-31/2). 
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3. 4 METHODS IN STUDY IV AND STUDY V 
3.4.1 Evaluation of peripheral or cerebrovascular disease among PD and HD patients 
In study IV peripheral vascular disease defined as presence of arterial insufficiency of the 
extremities, carotid or renal artery stenosis, or aortic aneurysm, and cerebrovascular disease, 
defined as presence of stroke, transient ischemic attack, subdural hematoma, and intracerebral 
or sub-arachnoid haemorrhage (88) was recorded and combined into one category, peripheral 
vascular disease or cerebrovascular disease, or both, PVCD. 
3.4.2 Blood sampling and laboratory analysis 
Plasma samples were taken and stored at -70°C, if not analysed immediately. Circulating levels 
of albumin (bromcresol purple), total cholesterol, creatinine and high-sensitivity C-reactive 
protein (hsCRP) were analysed using certified methods in the Department of Clinical Chemistry, 
Karolinska University Hospital Huddinge. Interleukin-6 (IL-6) was measured by Immulite 
immunoassay Analyzer (Siemens Healthcare, Erlanger, Germany), using assays manufactured 
for this analyser and according to the manufacturer’s instructions. The soluble form of vascular 
cell adhesion molecule 1 (sVCAM-1), a marker of endothelial activation, was analysed by 
commercial ELISA kits (R&D Systems Europe, Ltd, United Kingdom). 8-hydroxy-20-
deoxyguanosine (8-OHdG) was measured using a commercial competitive enzyme-linked 
immunosorbent assay kit (Japan Institute for the Control of Aging, Shizuoka, Japan), following 
the manufacturer’s instructions. Advanced oxidation protein products (AOPP) were analysed 
by a modified assay (84), correcting for impact of serum triglycerides to yield modified AOPP 
(mAOPP). 
In study IV plasma levels of sRAGE (Human RAGE Quantikine ELISA; R&D Systems, Inc., 
Minneapolis, MN, USA), S100A12 (Circulex S100A12/EN-RAGE ELISA kit; Cyclex Co.,  
Ltd., 1DJDQR-DSDQDQG1İ-(Carboxymethyl) lysine (CML; Cyclex Co., Ltd., Nagano, Japan) 
were measured using ELISA according to protocols provided by the manufacturer. 
In study V plasma pentosidine was analysed by reverse-phase high performance liquid 
chromatography (HPLC) as described previously (72). Circulating pentosidine is mainly present 
in protein bound form with albumin (69). Therefore, the total (free plus protein bound) plasma 
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pentosidine concentration, measured in nmol/L, was corrected for albumin and expressed as 
nmol of plasma pentosidine per gram of albumin. 
3.4.3 Nutritional status 
In all cohorts in study IV and study V, body mass index (BMI) was calculated as the body 
weight in kilograms divided by the square of patient height in meters. In addition subjective 
global assessment (SGA) was used to evaluate the overall protein-energy wasting (PEW) in 
CKD patients as described previously (89). Briefly, SGA score is based on six subjective 
assessments, three were based on the patient’s history of weight loss, incidence of anorexia or 
incidence of vomiting, and three were based on subjective grading of muscle wasting, presence 
of oedema and loss of subcutaneous fat. Then, each patient was given a score reflecting the 
overall nutritional status: 1 = normal nutrition, 2 = mild PEW, 3 = moderate PEW and 4 = severe 
PEW. In the current study, PEW was defined as SGA score >1. 
In study IV body composition was assessed in PD patients and controls, by dual energy x-ray 
absorptiometry (DEXA; Lunar Corp., Madison, WI, USA) estimating lean body mass (LBM) 
and fat body mass (FBM). In HD patients, FBM and LBM were assessed according to Durnin 
et al. (90) from biceps, triceps, subscapular, and supra-iliac skinfold thickness measurements 
with skinfold caliper (Cambridge Scientific Instruments, Cambridge, MD, USA); LBM (LBMI) 
and FBM (FBMI) indices were calculated according to Kyle et al. (91) and expressed as kg/m2.  
3.4.4 Statistical analysis  
In studies IV and V all statistical analyses were performed using statistical software SAS 
version 9.4 (SAS Campus Drive, Cary, NC, USA). Statistical significance was set at the level 
of p<0.05. Comparisons between 2 groups were assessed with non-parametric Wilcoxon test for 
FRQWLQXRXVYDULDEOHVDQGDȤWHVWIRUQRPLQDOYDULDEOHV'LIIHUHQFHVDPRQJWKUHHJURXSVZHUH
analysed using nonparametric ANOVA Kruskal-Wallis test followed by Dunn’s test. Non-
parametric Spearman rank correlation analysis was used to evaluate the association between 
parameters. 
In study IV data are expressed as mean ± standard deviation (SD) or median (range of 25 to 
75th percentile) or percentage, as appropriate. Multivariate logistic regression analyses were 
used to assess determinants of existing PVCD with data expressed as odds ratio, OR, with 95% 
22 
confidence intervals, 95% CI. A competing risk Cox regression model was used to analyse the 
independent risk of 2 events—renal transplantation or death. If a patient received renal 
transplantation, then the outcome of mortality was censored. A Cox model with a data 
augmentation method was used to analyse the competing risks. The two types of events were 
evaluated to see if they had a constant hazard ratio. Covariates were interacted with the outcome 
to analyse the independent effect of covariates on each of 2 competing endpoints. The 
cumulative incidence of events was calculated.  
In study V data are expressed as median (10 to 90th percentile) or percentage, or as relative risk 
(risk ratio), RR (95% CI, confidence intervals) as appropriate. To determine the adjusted RR for 
death associated with one standard deviation, 1-SD, higher pentosidine, multivariable 
GENMOD regression analysis was performed, see http://support.sas.com. Age, gender, diabetes 
(DM), SGA, hsCRP, 8-OHdG and patient cohorts were included in the model. A multiple 
imputation of missing values was performed using the function PROC MI, with all variables in 
the covariate section used to produce the values for imputation. The results for each imputation 
were generated by using PROC MIANALYZE and GENMOD regression analysis.  
Receiver operating characteristics (ROC) curves were analysed allowing calculation of areas 
under the curves (AUCs) and cut-off values for pentosidine in relation to all-cause and CVD-
related deaths.   
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4 RESULTS AND DISCUSSION 
4.1 STUDY I  
In this study we investigated the feasibility and impact of unplanned start educational 
programme (UPS-EP) intended to intervene in patient pathway and improving care of unplanned 
start (UPS) patients by facilitating care pathways and enabling informed choice of dialysis 
modality. 
 
From 270 patients enrolled in the study, 214 patients received UPS-EP and 56 never received 
UPS-UP. The patients who never received UPS-EP were significantly older (p=0.01), more 
comorbid (CCI, p<0.01), and they were distributed differently across the countries compared to 
those who received UPS-EP. There was a trend regarding patient source with a higher in-patient 
admission in the group who never received UPS- EP (p=0.09).  
 
Most of the patients (177/214) received UPS-EP immediately or shortly after UPS presentation, 
34 patients within the first 6 months after commencing dialysis, and 3 patients after 12 months. 
Whereas 203 out of the 214 UPS-EP patients completed the educational programme, 11 patients 
did not complete it because of their medical condition (n=8) or unwillingness to participate 
(n=3). Following the completion of UPS-EP, 177 patients made a decision on initial dialysis 
modality, 103 patients chose PD and 74 HD, while 26 patients did not make any choice, or were 
unable for clinical reasons to make a decision. The flow of patients through the UPS-EP is 
presented in Figure 4.1 
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Figure 4.1 Flow of 270 UPS patients through UPS-EP. 
 
The results of multivariate logistic regression analysis showed that having diabetes: OR= 1.88 
(CI, 1.05 – 3.37) and receiving UPS-EP: OR= 4.74 (CI, 2.05 – 10.98) were statistically 
significant predictors of receiving PD. 
 
From 177 patients who completed UPS-EP, 103 patients declared that they would choose PD 
and 74 patients that they would choose HD. Patients who chose PD were more comorbid (CCI, 
p=0.01), with higher prevalence of congestive heart failure (p<0.01), were distributed 
differently across countries (p<0.01) and with trend towards higher number of in-patient 
admissions (p=0.05) than in the patients choosing HD. 
  
Among the investigated UPS patients not everyone received the modality they selected after 
education. In our study, 89 patients chose and received PD and 70 patients chose and received 
HD according to their recorded decision. PD patients were significantly more comorbid (CCI, 
p=0.02), had more often medical history of congestive heart failure (p<0.001) and myocardial 
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infarction (p=0.02), were significantly more often from in-patient UPS admission (p=0.02) or 
referred from primary care (p=0.04), and were differently distributed among participating 
countries (p<0.001).  
Since not all the patients received their preferred therapy we compared patients who completed 
the UPS-EP according to the modality that they actually received.  
 
The results show that compared to those treated by HD, those treated by PD were significantly 
more comorbid (CCI, p=0.04), with higher prevalence of congestive heart failure (p<0.01) and, 
were significantly more often from in-patient admission (p=0.02), and referred from primary 
care (p=0.02), and were differently distributed among participating countries (p<0.001). 
  
Using Kaplan-Meier analysis we found no significant difference in one-year survival between 
patients who chose and received PD (n=89) and HD (n=70) and also there was no significant 
difference between patients who were actually treated with PD (n=93) and HD (n=84) 
respectively.  
 
The overall peritonitis rates in PD patients were lower than ISPD recommended goals (81). 
 
In study I we showed that it is feasible to provide a programme like UPS-EP to patients starting 
UPS dialysis; most patients were able to commence (79%) and complete education (75%). We 
confirmed the results of single centre studies (40, 41) showing that it is possible to commence 
UPS dialysis with PD. The OPTiONS study employed decision support tools which were shown 
to facilitate the decision making process by patients (92) and this helped the majority of patients 
to complete education and make a decision (66%) about their treatment option. 
 
Receiving UPS-EP education was a significant predictor of receiving PD in the logistic 
regression model. After making a decision, 103/177 patients - regardless of comorbidity 
disadvantages - selected PD. These results demonstrate that PD was not being selected only by 
younger and fitter patients and that a wide range of patients were receiving education and 
choosing PD. 
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It is noteworthy that throughout the study patients choosing and receiving PD and also those 
selecting and in fact being treated with PD were significantly more comorbid compared to their 
HD counterparts. Nevertheless, overall patient survival was the same in patients choosing and/or 
receiving PD compared to those treated by HD despite the age and comorbidity disadvantages 
in those treated by PD. Noteworthy, OPTiONS study was not powered to measure survival as a 
primary outcome measure and only one year follow up was performed; nevertheless, there are 
no indications that patients´ choice of modality associated with poor clinical outcomes in UPS 
patients. 
4.2 STUDY II 
In this study we investigated factors that may influence three key steps in the patient UPS-EP 
education within the OPTiONS study: (1) referral to and receiving UPS education, (2) making 
a decision about dialysis modality, (3) receiving the preferred dialysis modality after decision 
making (Figure 4.2). 
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Figure 4.2 Patients flow through the education pathway and application of regression models 
which have been developed to understand possible factors influencing the 3 key steps of the 
UPS-EP education pathway: receiving UPS-EP, decision making and enacting choice. 
 
We presented that patients who were older than 69 years had 60% lower chances of receiving 
education, OR=0.40 (CI, 0.20 – 0.80). Odds for receiving education were significantly higher 
among patients with PD as an initial dialysis modality, OR=4.81 (CI, 1.85 – 12.50). Also country 
was a significant predictor of receiving education, patients in Germany (DE), France (FR) and 
Austria (AU) had markedly lower chances of receiving education compared to patients from 
United Kingdom (UK), Sweden (SE) and Denmark (DK): OR = 0.38 (CI, 0.18 – 0.82).  
We showed that patients starting on PD as an initial dialysis modality OR=6.33 (CI, 2.89 – 
13.87) had significantly higher chances of making a decision about dialysis modality. Also 
country category was shown to be statistically significant predictors of decisions about dialysis 
modality: patients from DE, FR and AU had smaller chances of making a choice than patients 
from UK, SE and DK, OR=0.50 (0.28 – 0.87) 
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Regardless of the ability to make a dialysis modality decision after receiving education, there 
were still patients who did not receive the dialysis option according to their informed choice. 
We presented that while factors such as age, gender and DM failed to reach statistical 
significance as predictors for patients to receive their preferred option for initial dialysis 
modality, the only significant predictor was history of myocardial infarction, OR=0.15 (CI, 0.05 
– 0.48). Thus, patients with myocardial infarction were less likely to receive their preferred 
choice of final modality. 
 
We also performed a simple analysis of annual dialysis costs to assess the potential economic 
impact of UPS-EP which demonstrated potential cost savings of implementing the dialysis 
choice made by the UPS patients through UPS-EP. 
 
The majority of patients were able to receive UPS-EP. In our study the elderly patients were 
less likely to be referred for education. Also country factor and initial PD dialysis access were 
significant predictors of the referral to education.  
 
Regardless our findings, we believe that age should not be considered as contraindication for 
providing education and offering modality choice. Previous studies showed that elderly patients 
(93) have good clinical outcomes with PD and that age is not a barrier to choice of PD.  
 
The variability in PD usage between various parts of Europe is well known (26) and appears to 
reflect physician belief and practice patterns which are also playing out within the context of the 
current study. Our observation that initial dialysis access is a predictor of receiving education 
can reflect that physicians who firmly believe in patient choice of home dialysis with PD and 
support their willingness to commence PD are more likely to educate patients. 
 
The benefits of decision support tools in terms of improving knowledge and reducing decisional 
conflicts have been summarized in a recent systematic review (94). The OPTiONS study aimed 
to facilitate the decision making process by using decision support tools as a part  
of the programme. In the current study, age and comorbidity were not influential factors on 
decisions about dialysis modality. Thus these factors should not be used as part of value 
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judgements by clinical teams to assume which patients can or cannot make decisions; with the 
correct information and decision support, decision making is possible. Similar to the previous 
model, factors related to the country and the initial dialysis modality, were significant. Those 
findings emphasize again the difference in overall acceptance of patient centricity of physicians 
in clinical practice across Europe. 
 
The problem remains on the final step of the educational pathway, as the proposed model failed 
to identify significant factors influencing the enactment of patient preferred choice. Therefore, 
we suggest that pathway of care or logistic challenges which require further examination - in 
order to employ further interventions in clinical practice following patient education and 
decision making to ensure modality choice progresses - need to be identified and improved.  
4.3 STUDY III 
In the study III we aimed to examine firstly the putative differences in patients commencing 
unplanned dialysis with PD catheter or CVC as the starting access. Secondly, we examine the 
patients who switched the modality during the study including PD technique failure and HD to 
PD transfers to examine the overall patient pathway impact. Finally, we also investigate the 
predictors of permanent vascular access formation and clinical outcomes of patients undergoing 
only HD. 
 
Patients starting dialysis with PD catheter (n=72) were significantly older (p=0.02), had more 
comorbid conditions (CCI, p=0.001) with higher prevalence of diabetes (p=0.01), congestive 
heart failure (p<0.001) and myocardial infarction (p<0.01) and also had significantly different 
aetiology of CKD (p=0.001) compared to patients starting with CVC (n=198). The majority of 
patients were referred during an in-patient admission and referred to the nephrology unit from 
other hospital specialties. Patients starting with PD catheter had significantly lower number of 
procedures (p<0.001) throughout the entire study and significantly more of them received UPS-
EP (p=0.02) and were distributed differently across countries (p<0.001). 
From 72 patients who started dialysis with initial PD, 13 switched the therapy to HD. Patients 
who switched the therapy had significantly higher number of hospitalization events (p<0.01) 
and number of procedures (p<0.001) compared to those who remained on the therapy possibly 
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due at least in part by the need of new dialysis access. The crude technique survival for the 
patients at one year was 79% with transfer to PD usually occurring in the first 90-100 days. 
 
From 198 patients who commenced HD with CVC, 158 remained on this modality and 40 
switched the therapy. Patients who switched from HD to PD required access procedures more 
often (p<0.001) and were receiving unplanned start educational programme in higher proportion 
(p<0.001) compared to those who remained on HD throughout the study. The distribution of the 
countries differed significantly between those two groups. 
 
In our study, 85 patients commenced HD dialysis with CVC and remained with CVC and 73 
patients had permanent access with arteriovenous fistula (AVF) or graft. Patients who during 
the course of the study received permanent access were significantly younger (p<0.001), had 
lower prevalence of CHF (p<0.001), had higher number of hospitalization events (p<0.01), but 
did not stay significantly longer in hospital (p=0.18), and also had higher number and different 
distribution of access procedures (p<0.001). 
 
We showed in multivariate logistic regression analysis that age, OR= 0.34 (CI, 0.17 – 0.68), and 
congestive heart failure, OR= 0.31 (CI, 0.13 – 0.78), were significant predictors of receiving 
AV fistula: older patients had 66% lower chances of receiving AVF and patients with congestive 
heart failure had 69% lower chances of receiving AVF. 
 
The results of Cox regression analysis including adjustments for access (AVF or CVC), age, 
sex, country and CHF showed that younger patients: HR=0.39 (95% CI, 0.16 – 0.93) who 
received AVF had significantly lower risk of death, HR=0.11 (95% CI, 0.03 - 0.38). 
The majority of UPS patients commence dialysis with a CVC (36) and infrequently are able to 
transfer to PD (30) and indeed often remain dialysing with a CVC. The potential risks of long 
term use and CVC related complications are well-known (35). We showed that patients 
commencing dialysis with a PD catheter had fewer number of access procedures compared to 
those started with CVC, confirming this potential health system benefit. We observed no 
differences in regards to age and comorbidities between patients switching from PD to HD and 
those remaining on PD during the follow-up, confirming that PD can be a suitable modality in 
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these groups. Early modality switch from PD was associated with higher infection rates thus 
emphasizing the importance of the first 90 days in PD management (95). Interestingly, in the 
group who commenced HD with CVC group, 40/198 switched to PD and patients in this group 
were more likely to have received UPS-EP, leading us to conclude that this transfer was driven 
by patient choice. Similar to patients switching from PD to HD, patients switching from HD to 
PD were not different in terms of age or comorbidity compared to those remaining on HD during 
the follow-up. Therefore, there was no evidence that younger or healthier patients were 
preferentially transferred. 
 
There is evidence (31) and clinical guideline recommendations (96) stressing the importance of 
the benefit of permanent access with AVF compared to CVC. Studies have observed the survival 
challenges associated with suboptimal dialysis start with CVCs (27). Throughout our study, 
73/158 patients who had a reported permanent access procedure were younger and less 
frequently had cardiac failure compared to patients who remained on CVC. It appears that it is 
likely that the HD patients who never received a permanent access procedure contains a group 
of patients in whom the physician is actively deciding to try to maintain a CVC, particularly 
among older and those with cardiac failure. This is confirmed by logistic regression analysis 
where younger age and lack of congestive heart failure were significant factors determining the 
presence of permanent access, and also AVF and younger age was associated with better one-
year survival. 
4.4 STUDY IV 
In the study IV we evaluated circulating S100A12 and sRAGE in relation to vascular disease, 
inflammation, nutritional status, and mortality risk in PD patients. We compared PD, HD and 
control individuals. Compared with the HD patients, median S100A12 was 1.9 times higher, 
median sRAGE lower by 14%, and median S100A12/sRAGE 2.4 times higher in PD patients. 
Among PD patients 25% were high or high-average (53%) transporters, while 3% were low or 
low-average (19%) transporters; however, plasma S100A12 and sRAGE levels were not 
significantly different between the transport groups. 
The results from univariate analysis showed WKDW LQ3'6$DVVRFLDWHVZLWK&53ȡ 
0.47; p < 0.001), IL-ȡ SDQGP$233ȡ S DQGQHJDWLYHO\
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ZLWKDOEXPLQȡ -S.W9ȡ -S DQG*)5ȡ -0.22; p = 0.07). 
Soluble RAGE levels assocLDWHGQHJDWLYHO\ZLWK%0,ȡ -S)%0,ȡ -0.34; p 
DQG/%0,ȡ -0.37; p < 0.05). 
 
Multivariate logistic regression analysis showed that peripheral or cerebrovascular disease 
(PCVD) was associated mainly with high level of S100A12, OR=3.52 (CI, 1.09 – 11.41). 
 
The mean follow-up for PD patients was 31 months, and during that time 23 PD patients died 
and 19 patients underwent kidney transplantation. Median S100A12 at baseline was higher in 
23 non-survivors (36 [11 – 62] ng/mL, p < 0.05) than in 59 survivors who remained on PD (n = 
40; 23 [16 – 31] ng/mL) or underwent renal transplantation (n = 19; 29 [23 – 54] ng/mL) while 
no such differences were found for sRAGE (p=0.26). The competing risk Cox regression 
analysis showed that the highest tertile of S100A12 versus the 2 other tertiles associated with 
increased mortality (Figure 4.3 A) No associations were found for sRAGE or S100A12/sRAGE 
ratio. In addition to high S100A12, presence of CVD was also a significant predictor of mortality 
in PD patients. 
 
The median follow-up for HD patients was 29 months, and during that time 87 patients died and 
38 underwent kidney transplantation. Median S100A12 at baseline was higher in non-survivors 
(n=87; 36 [11 – 62] ng/mL, p < 0.01) than in 103 survivors who remained on HD (n = 65; 23 
[16 – 31] ng/mL) or who underwent renal transplantation (n = 38; 29 [23 – 54] ng/mL) while 
no such differences were found for sRAGE in HD patients (p=0.61). Similar to the case for PD 
patients, the competing risk Cox regression analysis showed that the highest tertile versus 
middle and lowest tertiles of S100A12 associated with increased mortality while no such 
associations were found for sRAGE or S100A12/sRAGE ratio (Figure 4.3 B). In addition to 
high S100A12, high age (>65 years) was also a significant predictor of mortality in HD patients. 
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Figure 4.3 Cumulative incidence rate for the competing end-point of renal transplantation and 
death in patients with highest tertile of S100A12 versus the lower tertiles of S100A12 in PD 
(Fig 4.3 A) and HD (Fig 4.3 B). 
       A      B 
 
In study IV we presented that S100A12, known to have a pro-inflammatory role, is associated 
with biomarkers of inflammation and with PCVD, suggesting that the mortality-predictive role 
of S100A12 is linked to vascular disease involving inflammatory mediators. We also presented 
that sRAGE, which is thought to be anti-inflammatory and protective against atherosclerotic 
CVD was not associated with inflammation, comorbidity and mortality. Interestingly, in 
prevalent PD patients, we found that sRAGE was inversely correlated to indices of body mass 
such as: BMI, FBMI, and LBMI. Levels of sRAGE are generally lower in patients with chronic 
inflammatory conditions, and plasma endogenous RAGE was reported to be inversely correlated 
with components of the metabolic syndrome including obesity (60). Also of interest in study 
IV was that S100A12, sRAGE, and S100A12/sRAGE levels were markedly elevated in PD 
patients. In the state of uraemia, the production of AGEs is increased resulting in up-regulation 
of RAGE which could promote peritoneal fibrosis and vascular sclerosis (97), and exposure to 
high glucose PD fluids may further contribute to such changes (98). Not surprisingly, sRAGE 
and S100A12 accumulate in PD patients (64, 65, 99) as shown also in the current study, and 
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hyperglycemia-induced reactive oxygen species may further increase expression of RAGE and 
RAGE-ligands (100). 
 
Although the median S100A12 concentration was 1.9 times higher and the median 
S100A12/sRAGE ratio 2.4 times higher in PD patients than in HD patients, this difference could 
not be explained by the inflammation status as median CRP and IL-6 levels were higher in HD 
than in PD patients. We suggest that the difference may be related to differences between the 
two dialysis modalities implicating that stimulation of the AGE-RAGE system by glucose-based 
PD dialysis solutions could be of importance although it is likely that differences in patient 
characteristics or medications or other factors may also play a role.  
 
Finally, in study IV we showed that high level of S100A12, in prevalent PD patients is 
associated with mortality. Our results are in accordance with previous studies showing similar 
results in patients with CKD stage 5 before starting dialysis (65) and in prevalent HD patients 
(66). 
4.5 STUDY V 
In study V we measured plasma pentosidine in 746 patients with different stages of CKD and 
undergoing different dialysis treatments including PD and HD, explored factors potentially 
linked to an increased level of pentosidine, and analysed the association of pentosidine with 
cardiovascular and all-cause mortality. The studied population consisted of 746 individuals with 
different stages of CKD including: CKD stage 1–2 (n=37) and CKD stage 3–4 (n=54), incident 
pre-dialysis CKD stage 5 patients (CKD5-ND; n=386) and prevalent PD (n=74) and HD 
(n=195) patients. The groups differed in regards to age with the youngest patients in the CKD5-
ND group (median, 55 years) and the oldest in the CKD1-2 group (median, 68 years). Diabetes 
was most common in CKD stage 3–4 group (44%), and malnutrition (45%) and CVD (61%) 
most common among the HD patients. The highest level of inflammatory and oxidative stress 
biomarkers was also among HD patients (hsCRP: median 6.5mg/L and 8-OHdG: median 1.3 
ng/ml). 
We observed a trend of increasing pentosidine level with the progression of CKD stages. 
Compared to CKD stage 1 group, CKD5-ND, and PD and HD patients had higher pentosidine 
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levels. The level of pentosidine in PD patients was significantly lower compared to HD patients, 
but not different compared to CKD5-ND patients (Figure 4.4 A)  
Subgroup analysis showed no significant difference in plasma pentosidine levels between 
diabetes (DM) and non-diabetes (non-DM) patients in any of the group or for the combined 
cohort. In the combined cohort of all investigated individual (n=746) there were significant (all 
p<0.0001) correlations between plasma pentosidine and markers of inflammation (hsCRP, IL-
6), oxidative stress (8-OHdG) and eGFR. Figure 4.4 B presents the relation between pentosidine 
and eGFR in all 746 individuals.  
 
Figure 4.4 Baseline plasma pentosidine concentration, corrected for albumin level, and shown 
as box-and-whisker plots depicting median, and 10th to 90th percentile for each studied cohort 
(panel A). Correlations including all individuals (panel B; n=746) between plasma pentosidine 
level, corrected for albumin, and estimated glomerular filtration rate (eGFR) calculated by the 
chronic kidney disease epidemiology collaboration (CKD-EPI) formula or, in haemodialysis 
patients, assuming eGFR to be zero.  
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In the multivariate linear regression analysis, higher age, malnutrition (SGA), oxidative stress 
(8-OHdG, 1-SD higher), and belonging to the CKD5-ND, HD and PD cohorts were significant 
predictors of 1-SD higher pentosidine in the combined cohort of all 746 individuals after 
adjusting for sex, presence of DM, and inflammation (hsCRP).  The applied model shows that 
being an ESRD patient (CKD5-ND, HD and PD cohorts) vs being a CKD 1–2 patient explains 
much of the variation in pentosidine level in parallel with higher age, malnutrition and oxidative 
stress. 
 
The all-cause and cardiovascular mortality occurring within 60 months, in the combined group 
of all individuals (n = 746) was significantly associated with 1-SD higher pentosidine, RR = 
1.04 (CI, 1.01–1.08, p = 0.01) and RR = 1.03 (CI, 1.01–1.06, p = 0.03) respectively, after 
adjustment for confounders: age, gender, CVD, DM, SGA, hsCRP (1-SD higher), 8-OHdG (1-
SD higher) and cohort.  
In study V we reported that plasma pentosidine is markedly elevated in patients with CKD and 
differed between the dialysis modalities (PD patients had significantly lower level of 
pentosidine compared to HD patients) suggesting that dialysis modality has an impact on 
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pentosidine level. High pentosidine concentration was associated with low GFR, and signs of 
oxidative stress and inflammation and, in addition, age, malnutrition, oxidative stress (8-OHdG) 
and group entities were significant predictors of a 1-SD higher pentosidine level. Thus, whereas 
variations in plasma pentosidine concentrations may to a large extent be explained by RRF, also 
higher age, an increased pro-oxidative state, and malnutrition, which are typical findings in 
uremic patients, as well as characteristics specific for each CKD stage or dialysis modality may 
also play a role. It was presented before that the accumulation of AGEs increases with the 
decline of renal function (69, 101). Studies in PD patients showed that loss of RRF is associated 
with increased plasma pentosidine and AOPP, showing the beneficial role of RRF in reducing 
oxidative and carbonyl stress (71). We found no significant differences in plasma pentosidine 
level between DM and non-DM patients in any of our studied cohort, and in multivariate 
analysis, DM was not a significant predictor of the pentosidine level. This may suggest that  
enhanced production and accumulation of AGEs among patients with impaired renal function 
is mainly related to conditions other than hyperglycaemia (102) and any added effect of 
glycation is attenuated by the effect of kidney failure and uremia (69). The survival analysis 
showed that 1-SD higher pentosidine was a significant, independent predictor of all-cause and 
CVD mortality after adjustment for confounders showing the putative usefulness of pentosidine 
as a biomarker and possible role as potential target for interventions aiming at improving clinical 
outcomes of patients with ESRD. 
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4.6 STRENGTHS AND LIMITATIONS 
4.6.1 Strengths 
As OPTiONS was a multicentre study in 6 European countries and 26 dialysis units our findings 
may be applicable in different settings thus increasing the external validity of the study. The 
broad inclusion criteria allowed the inclusion of all UPS patients and not only a selected group 
who professionals deemed to be appropriate for education. It is noteworthy that the study was 
conducted in real world clinical settings allowing monitoring of all aspects related to specific 
conditions of unplanned dialysis start. We also presented novel findings in regards to the area 
of patient education. In study I, we showed the feasibility and effectiveness of UPS-EP. In study 
II, we determined factors that may influence the educational pathway of the UPS patient and, in 
study III, we presented patient outcomes and healthcare utilisation in UPS patients depending 
on initial dialysis access (CVC or PD catheter) and subsequent patient pathway. In studies IV 
and V, we used the material from well phenotyped cohorts and presented novel findings 
regarding the prognostic role of biomarkers that are part of the AGE-RAGE pathway. In study 
IV, to the best of our knowledge, we are the first to show that a high level of S100A12 associates 
with mortality in prevalent PD patients. In study V, we presented determinants of plasma 
pentosidine in patients with various CKD stages and using different dialysis modalities and 
proved its association with cardiovascular and all-cause mortality. 
4.6.2 Limitations 
Several limitations in our studies should be acknowledged. In the OPTiONS study, patients were 
followed up for only 12 months; therefore we could only speculate about the long term clinical 
outcomes of patients who participated in the study. The study had non-interventional design 
with no control group; however the ethical aspect of including a control group should be noted 
as inclusion of controls would result in deprivation of the education in one of the included 
groups. We had no biochemical measurements available and we did not monitor the levels of 
biomarkers in the OPTiONS study; such information could have provided clinically relevant 
information and increased the value of the study. Also we did not follow patients prior to 
enrolment; thus we were unable to analyse the pre-dialysis factors related to the dialysis 
initiation. In the biomarker studies, due to cross sectional nature of study IV and V, we are 
unable to state any conclusion about causality of the observed association of mortality with 
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S100A12, sRAGE and pentosidine. We collected samples for measurement of biomarkers only 
at a single time point (baseline); therefore, we could not speculate about the variations of the 
investigated biomarkers over time.  
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